Preoperative coagulation assessment of patients on apixaban and rivaroxaban undergoing hip fracture surgery by chromogenic antiXa assays and rotational thrombelastometry (ROTEM®)
- Conditions
- Hip fractureS72.9Fracture of femur, part unspecified
- Registration Number
- DRKS00008834
- Lead Sponsor
- niversitätsklinik Wien
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting withdrawn before recruiting started
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Intake of apixaban or rivaroxaban and planned hip fracture surgery
Exclusion Criteria
None
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Specific antiXa values will be measured at certain time points (as described below) and analysed for possible correlation with intraoperative blood loss.<br>Time points of blood sampling: admission, 24 and 48 hours after the last intake of medication (apixaban or rivaroxaban) and at the time of surgery.<br>Measurement: Chromogenic antiXa measurement will be performed on a STA-R Evolution coagulometer (Diagnostica Stago S.A.S., Asnières sur Seine, France) in citrated plasma obtained by centrifugation. BIOPHEN DiXa-I (Hyphen-Biomed, Neuville-sur-Oise, France) will be used for the measurements.
- Secondary Outcome Measures
Name Time Method owTF-ROTEM® at the time of surgery will be analysed for possible correlation with intraoperative blood loss.